Skip to main content
. 2015 Jan 26;4:4. doi: 10.1186/2162-3619-4-4

Table 2.

Number of bound CD20 antibodies per lymphoma cell before and after valproate treatment

Patient Valproate dosage (mg/kg/day) Day 0 Day 3
MFI Bound CD20 mAbs per cell MFI Bound CD20 mAbs per cell Plasma valproate (μM)
003 30 2163 6866 7602 18035 *407
008 80 30893 70229 34322 78890 656
010 80 35540 69096 41605 79260 847

An FNB of an affected lymph node was performed before treatment start as well as morning day 3, cycle 1 in patients 003, 008 and 010 of the VALFRID study. Lymphoma cells (i.e., monoclonal B-cells) were analysed by FACS as described in materials and methods, and the number of bound CD20 antibodies to the cell surface was calculated by normalisation by the QuantiBRITE assay using geometric mean fluorescence intensity (MFI). Corresponding doses and serum levels of valproate are indicated (*: Day 2).